According to forecasts, the Molecular Imaging Market is expected to be US$ 5,437.16 million in 2023 and US$ 15,457.48 million by 2033.
The need for early illness diagnosis is increasing due to the rising incidence of numerous chronic diseases like cancer and other genetic disorders, which is anticipated to fuel the expansion of the worldwide market.
According to data from the Centers for Disease Control and Prevention (CDC) from February 2018, over 22,000 men and 9,000 women in the United States are diagnosed with liver cancer each year, and approximately 16,000 men and 8,000 women pass away from the disease. In addition, the market’s revenue growth is fueled by the rapid progress of molecular imaging technologies.
Experience The Cutting-Edge Of Innovation And Success With Our Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-724
In the biomedical business, immune-PET, for instance, has considerably improved early cancer cell identification, enabling more use. The clinical benefit of targeted treatment using monoclonal antibodies is maximized by selecting the proper medication for the right patient.
Immune PET imaging makes it possible to assess these drugs’ in vivo biodistribution and tumor targeting to predict their toxicity and effectiveness, guide drug research, and provide specialized care. As a molecular imaging biomarker for assessing target expression and tumor targeting, radio-labeled monoclonal antibodies enable viewing and measurement of the tracer uptake.
Key Takeaways
- In 2022, North America’s molecular imaging market expanded, with a CAGR of 35.1%.
- In 2022, the United States developed the molecular imaging business with a share of 22.6%.
- The molecular imaging market grew considerably to US$ 4,855.5 million in 2022.
- The molecular imaging market expanded with a CAGR of 9.3% between 2018 to 2022.
- By 2033, China’s molecular imaging market is projected to develop with a CAGR of 10.3%.
- By 2033, India’s molecular imaging industry is projected to expand with a CAGR of 11%.
- Japan’s molecular imaging industry grew significantly, with a 3.6% share in 2022.
- Australia’s molecular imaging market is likely to expand with a CAGR of 12.7% by 2033.
- Germany’s molecular imaging business grew, with a share of 6.9% in 2022
- In 2022, based on modality, SPECT dominated the market, with a share of 23.5%.
- In 2022, the hospital’s segment led the market, with a share of 56.5%, based on the end user.
Key Players’ Strategies and Recent Developments:
- NXC Imaging, a distributor and service provider of medical imaging equipment in Minneapolis, Minnesota, was purchased by Canon Medical Systems, United States, on July 27, 2022. It’s a commercial firm and a global leader in cutting-edge diagnostic imaging technology. Through the strategic partnership between NXC Imaging and Canon Medical Systems United States, the sales and service reach of the Upper Midwest region increased and enhanced.
- The world’s first digital SPECT/CT with high-energy imaging was introduced on October 18, 2022, by Spectrum Dynamics Medical, a Swiss manufacturer of biomedical instruments. This innovation enables nuclear medicine clinics to offer a complete spectrum of clinical services. This capability is present in the new VERITON-CT 400 Series Digital SPECT/CT scanners, allowing imaging applications for the entire body, the heart, the brain, and other organs.
Embrace Smarter Choices With Our Methodology-Derived Insights Today! https://www.futuremarketinsights.com/request-report-methodology/rep-gb-724
Key players:
- Hermes Medical Solutions
- Bruker Corporation
- GE Company
- Fujifilm Holdings Corp.
- Koninklijke Philips N.V.
- Siemens AG
- Toshiba Medical System Corp.
- Mirada Medical Limited
- Carestream Health, Inc.
- Esaote SpA
- Positron Corporation
- Medisco Ltd.
- Hitachi Medical Corp.
- MIM Software Inc.
Key segments
By Modality:
- Molecular Ultrasound Imaging
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
- Nuclear Magnetic Resonance (NMR) Spectrometer
- Hybrid Products
By Application:
- Cardiovascular
- Neurology
- Oncology
- Respiratory
- Gastrointestinal
By End Users:
- Hospitals
- Diagnostic Imaging Centres
- Ambulatory Surgical Centres
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube